Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: Preliminary results

Rheumatology International

Volumn 26, Issue 4, 2006, Pages 340-347

  Boehme, Michael W J ^a,e   Gao, Ino K ^b   Norden, Cornelia ^c   Lemmel, Ernst Martin ^d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Rheumatology Practice   (Germany)

^c BAYER PHARMA AG   (Germany)

^d Max Grundig Clinic   (Germany)

^e Public Health Office   (Germany)

Author keywords

Adhesion molecules; Endothelial cells; Iloprost; Rheumatoid arthritis; Thrombomodulin

Indexed keywords

CELL ADHESION MOLECULE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ILOPROST; INTERCELLULAR ADHESION MOLECULE 1; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DAMAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOMODULATION; MALE; MEDICAL PARAMETERS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SELF EVALUATION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; ILOPROST; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PLATELET AGGREGATION INHIBITORS; SEVERITY OF ILLNESS INDEX; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE-1;

EID: 30744459364     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0563-9     Document Type: Article

References (70)

1. Gay S, Gay RE, Koopman W (1993) Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis:two cellular mechanisms explain joint destruction. Ann Rheum Dis 52:S39-S47
2. Fitzgerald O, Bresnihan B (1995) Synovial membrane cellularity and vascularity. Ann Rheum Dis 54:511-515
3. Klareskog L, Ronnelid J, Holm G (1995) Immunopathogenesis and immunotherapy in rheumatoid arthritis:An area in transition. J Int Med 238:191-201
4. Szekynecz Z, Koch AE, Kunkel SL, Strieter RM (1998) Cytokines in rheumatoid arthritis. Potential targets for pharmacological interventions. Drug Ageing 12:377-390
5. Feldmann M, Brennan FM, Maini RN (1995) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14:397-440
6. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247
7. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan, FM, Walker J, Bijl H, Ghrayeb J, Woody JN (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36:1681-1690
8. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor ∀(cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127
9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettinger RE, Cohan S, Koopman WJ, Mohler K, Widmer MB, Blosch CM (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc-fusion protein. N Engl J Med 337:141-147
10. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M (1996) IL-1-Ra arthritis study group, Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39:1092-1101
11. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Roman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41:2196-2204
12. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196
13. Cronstein BN (1994) Adhesion molecules in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 6:300-304
14. Carlos TM, Harlan JM (1994) Leukocyte-endothelial adhesion molecules. Blood 84:2068-2101
15. Gearing AJH, Newman W (1993) Circulating adhesion molecules in disease. Immunol Today 14:506-512
16. Gearing AJH, Hemingway I, Pigott R, Hughes J, Rees AJ, Cashman SJ (1992) Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, VCAM-1: pathological significance. Ann NY Acad Sci 667:324-331
17. Cush JJ, Rothlein R, Lindsley HB, Mainolfi EA, Lipsky PE (1993) Increased levels of circulating intercellular adhesion molecules 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098-1102
18. Mason JC, Kapahi P, Haskard DO (1993) Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecules. Arthritis Rheum 36:519-527
19. Wellicome SM, Kapahi P, Mason JC, Lebranchu Y, Yarwood H, Haskard DO (1993) Detection of circulating form of vascular cell adhesion molecule 1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 92:412-418
20. Blann AD, McCollum CN, Steiner M, Jayson MIV (1995) Circulating adhesion molecules in inflammatory and atherosclerotic vascular disease. Immunol Today 16:251-252
21. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN (1996) Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor antibody in rheumatoid arthritis. Arthritis Rheum 39:1082-1091
22. Grant SM, Goa KL (1992) Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular procedures. Drugs 43:889-924
23. Jörres A, Luttmann W, Scholz P; Thierauch K-H, Gahl GM, Topley N, Frei U, Blitstein-Willinger E (1994) Specific inhibition of tumor necrosis factor in endotoxin-stimulated mononuclear leukocytes by prostacyclin analogue iloprost. Clin Intensive Care 5:296-302
24. Jörres A, Dinter H, Topley N, Gahl GM, Frei U, Scholz P (1997) Inhibition of tumour necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: cellular mechanisms. Cytokine 9:119-125
25. Hildebrand M, Kraus C, Windt-Hanke F, Iffert B, Scheuermann H (1995) In vitro/in-vivo correlation of drug liberation with an extended release peroral dosage form for iloprost in man. Drug Dev Ind Pharm 21:2339-2353
26. Gao IK, Scholz P, Boehme MWJ, Norden C, Lemmel EM (2002) A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analogue iloprost: cytokine modulation, safety, and clinical effects. Rheumatol Int 22:45-51
27. Esmon CT, Owen WG (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78:2249-2252
28. Dittman WA, Majerus PW (1990) Structure and function of thrombomodulin a natural anticoagulant. Blood 75:329-336
29. Ishii H, Yama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618-623
30. Sawada K, Yamamoto H, Yago H, Suehiro S (1992) A simple assay to detect endothelial cell injury; measurement of released thrombomodulin from cells. Exp Mol Pathol 57:116-123
31. Boehme MWJ, Deng Y, Raeth U, Bierhaus A, Ziegler R, Stremmel W, Nawroth PP (1996) Release of thrombomodulin from endothelial cells by concerted action of TNFα and neutrophils: in vivo and in vitro studies. Immunology 87:134-140
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller J-G, Sharp J-T, Wilder RI, Hunter GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
33. Heijde van der DMFM, Hof van MA, Riel van PLCM, Leeuwen van MA, Rijswijk van HM, Putte van de LBA (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177-181
34. Riel van PLCM (1992) Provisional guidelines for measuring disease activity in clinical trials on rheumatoid arthritis. Br J Rheumatol 31:793-794
35. Bevilacqua MP (1993) Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 11:767-804
36. Gonzalez-Amaro R, Sanchez-Madrid F (1999) Cell adhesion molecules: selectins and integrins. Crit Rev Immunol 19:389-429
37. Seth R, Raymond FD, Makgoba MW (1991) Circulating ICAM-1 isoforms: diagnostic prospects for inflammatory and immune disorders. Lancet 338:83-84
38. Pigott R, Dillon LP, Hemingway IH, Gearing AJH (1992) Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589
39. Leeuwenberg JFM, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TMAA, Ahern TJ, Buurman WA (1992) E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 77:543-549
40. Hashimoto M, Shingu M, Ezaki I, Nobunga M, Minamihara M, Kato K, Sumioki H (1994) Production of soluble ICAM-1 from human endothelial cells induced by IL-1γ and TNF-α. Inflammation 18:163-173
41. Koch AE, Burriws JC, Haines GK, Carlos TM, Harlan JM, Leibovich SJ (1991) Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 64:313-320
42. Wilkinson LS, Edwards JCW, Poston RN, Haskard DO (1993) Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. Lab Invest 68:82-88
43. Hale LP, Martin ME, McCollum DE, Nunley JA, Springer TA, Singer KH, Haynes BF (1989) Immunhistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenviroment. Arthritis Rheum 32:22-30
44. Shinsaku S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483-1493
45. Furuzawa-Carballeda J, Alcover-Varela J (1999) Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis. Scand J Immunol 50:215-222
46. Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, Meinders AE, Maini RN (1996) Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 39:1077-1082
47. Smith MD, Slavotinek J, Au V, Weedon H, Parker A, Coleman M, Poberts-Thomson PJ, Ahern MJ (2001) Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. Rheumatology 40:965-977
48. Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliot MJ, McCloskey R, Feldmann M, Maini RN (2000) Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. Arthritis Rheum 43:38-47
49. Voskuyl AE, Martin S, Melchers L, Zwinderman AH, Weichselbraun I, Breedveld FC (1995) Levels of circulating intercellular adhesion molecule-1 and -3 but not circulating endothelial leukocyte adhesion molecule are increased in patients with rheumatoid vasculitis. Br J Rheumatol 34:311-315
50. Kolopp-Sarda MN, Guillemin F, Chary-Valckenaere I, Bene MC, Pourel J, Faure GC (2001) Longitudinal study of rheumatoid arthritis patients discloses sustained elevated serum levels of soluble CD106 (V-CAM). Clin Exp Rheumatol 19:165-170
51. Machold KP, Kiener HP, Graininger W, Graininger WB (1993) Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 68:74-78
52. Littler AJ, Buckley CD, Wordsworth P, Collins I, Martinson J, Simmons DL (1997) A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol 36:164-169
53. Tokuhira M, Hosaka S, Volin MV, Haines GK, Katschke KJ, Kim S, Koch AE (2000) Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis. Arthritis Rheum 43:1122-1133
54. Kuuliala A, Eberhardt K, Takala A, Kautainen H, Repo H, Leirisalo-Repo M (2002) Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five-year study. Ann Rheum Dis 61:242-246
55. Veale DJ, Maple C, Kirk G, McLaren M, Belch JJ (1998) Soluble cell adhesion molecules P-selectin and ICAM-1, and disease activity in patients receiving sulphasalazine for active rheumatoid arthritis. Scand J Rheum 27:296-299
56. Grundmann HJ, Hähnle U, Hegenscheid B, Sahlmäller G, Bienzle U, Blitstein-Willinger E (1992) Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis 165:501-505
57. Darius H, Veit K, Binz C, Fisch A, Meyer J (1995) Diminished inhibition of adhesion molecule expression in prostacyclin receptors desensitized human platelets. Agents Actions Suppl 45:77-83
58. Fischer CA, Kappa JR, Sinha AK, Cottrell ED, Reiser HJ, Addonizio VP (1987) Comparison of equimolar concentrations of iloprost, prostacyclin and prostaglandin E1 on human platelets function. J Lab Clin Med 109:184-190
59. Della Bella S, Molteni M, Compasso S, Zulian C, Vanoli M, Scorza R (1997) Differential effects of cyclooxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids 56:177-184
60. Czeslick EG, Simm A, Ground S, Sliber RE, Sablotzki A (2003) Inhibition of intracellular tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest 33:1013-1017
61. Mazzone A, Faggioli P, Cusa C, Stefanin C, Rondena M, Morelli B (2002) Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia. Eur J Clin Invest 32:882-888
62. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostag Other Lip Mediat 65:73-83
63. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N (1994) Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol 101:109-113
64. Boehme MWJ, Schmitt WH, Youinou P, Stremmel WR, Gross WL (1996) Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 101:387-394
65. Boehme MWJ, Raeth U, Galle PR, Stremmel W, Scherbaum WA (2000) Serum thrombomodulin - a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 119:189-195
66. Candela M, Pansoni A, Jannino L, Menditto VG, Natalini M, Ravaglia F, DaLio L, Scorza R, Gabrielli A, Danieli G (2001) Coagulative modifications in patients with systemic sclerosis treated with iloprost or nifedipine. Ann Ital Med Int 16:170-174
67. Vayssairat M (1996) Controlled multicenter double blind trial on an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. J Rheumatol 23:1917-1920
68. Hayakawa T, Shouzu A, Nishikawa M, Miyake Y, Shimizu H, Omoto S, Inada M (2000) Effects of beraprost and cilostazol and renal function on serum thrombomodulin levels in diabetic patients. Arzneimittelforschung 20:535-538
69. Moncada S, Higgs EA, Vane JR (1977) Human arterial and venous tissue generates prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1:18-20
70. Moncada S (1982) Prostacyclin and arterial wall biology. Arteriosclerosis 2:193-202